Kainova Therapeutics is a clinical-stage biopharmaceutical company focused on modulating G protein-coupled receptors (GPCRs) to improve patient outcomes in immuno-oncology and inflammation. The company’s lead program is a clinical-stage, Treg-depleting anti-CCR8 antibody that management says offers differentiated competitive features. A second program, currently at the pre-IND stage, is a first-in-class biased antagonist of PAR2 aimed at inflammatory pathways. By advancing these assets, Kainova seeks to build a diversified pipeline of GPCR-targeting therapies that can address multiple high-value indications. The firm operates across North America, France, and Australia, leveraging global clinical infrastructure. Proceeds from its recent Series B financing will be used to move its GPCR programs further into clinical development. No revenue, patient enrollment, or other operating metrics were disclosed, reflecting its pre-commercial status.

Total raised

$24M

Funding rounds

1

Latest round

Series B

Latest activity

Feb 2026